Ownby RL, Crocco E, Acevedo A, et al. Depression and risk for Alzheimer disease: systematic review, meta-analysis, and meta-regression analysis. Arch Gen Psychiatry 2006; 63: 530–8 ArticlePubMed Google Scholar
Lopez OL, Becker JT, Sweet RA, et al. Psychiatric symptoms vary with the severity of dementia in probable Alzheimer’s disease. J Neuropsychiatry Clin Neurosci 2003; 15: 346–53 ArticlePubMed Google Scholar
Roberson ED, Mucke L. 100 years and counting: prospects for defeating Alzheimer’s disease. Science 2006; 314: 781–4 ArticlePubMed Google Scholar
Folwell J, Cowan CM, Ubhi KK, et al. Abeta exacerbates the neuronal dysfunction caused by human tau expression in a Drosophila model of Alzheimer’s disease. Exp Neurol 2010 Jun; 223(2): 401–9 ArticlePubMedCAS Google Scholar
Winblad B. Socio-economic perspectives of dementia and cost-effectiveness of treatment. 7th International Geneva/Springfield Symposium on Advances in Alzheimer Therapy; 2002 Apr 3–6; Geneva
Hebert LE, Scherr PA, Bienias JL, et al. Alzheimer disease in the US population: prevalence estimates using the 2000 census. Arch Neurol 2003; 60: 1119–22 ArticlePubMed Google Scholar
Rösler M, Anand R, Cicin-Sain A, et al. Efficacy and safety of rivastigmine in patients with Alzheimer’s disease: international randomised controlled trial. BMJ 1999; 318: 633–8 ArticlePubMed Google Scholar
Wilcock GK, Lilienfeld S, Gaens E. Efficacy and safety of galantamine in patients with mild to moderate Alzheimer’s disease: multicentre randomised controlled trial. BMJ 2000; 321: 1445–9 ArticlePubMedCAS Google Scholar
Winblad B, Wimo A, Engedal K, et al. 3-Year study of donepezil therapy in Alzheimer’s disease: effects of early and continuous therapy. Dement Geriatr Cogn Disord 2006; 21: 353–63 ArticlePubMedCAS Google Scholar
Black S, Doody R, Li H, et al. Donepezil preserves cognition and global function in patients with severe Alzheimer disease. Neurology 2007; 69: 459–69 ArticlePubMedCAS Google Scholar
Winblad B, Kilander L, Eriksson S, et al. Donepezil in patients with severe Alzheimer’s disease: double-blind, parallel-group, placebo-controlled study. Lancet 2006; 367: 1057–65 ArticlePubMedCAS Google Scholar
Feldman H, Gauthier S, Hecker J, et al. A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimer’s disease. Neurology 2001; 57: 613–20 ArticlePubMedCAS Google Scholar
Seltzer B, Zolnouni P, Nunez M, et al. Efficacy of donepezil in early-stage Alzheimer disease: a randomized placebo-controlled trial. Arch Neurol 2004; 61: 1852–6 ArticlePubMed Google Scholar
Ritchie CW, Ames D, Clayton T, et al. Metaanalysis of randomized trials of the efficacy and safety of donepezil, galantamine, and rivastigmine for the treatment of Alzheimer disease. Am J Geriatr Psychiatry 2004 Jul–Aug; 12(4): 358–69 PubMed Google Scholar
Hansen RA, Gartlehner G, Webb AP, et al. Efficacy and safety of donepezil, galantamine, and rivastigmine for the treatment of Alzheimer’s disease: a systematic review and meta-analysis. Clin Interv Aging 2008; 3(2): 211–25 PubMedCAS Google Scholar
Winblad B, Poritis N. Memantine in severe dementia: results of the M-BEST study (benefit and efficacy in severely demented patients during treatment with memantine). Int J Geriatr Psychiatry 1999; 14: 135–46 ArticlePubMedCAS Google Scholar
Reisberg B, Doody R, Stöffler A, et al. Memantine in moderate-to-severe Alzheimer’s disease. N Engl J Med 2003; 348: 1333–41 ArticlePubMedCAS Google Scholar
Dysken MW, Mendels J, LeWitt P, et al. Milacemide: a placebo-controlled study in senile dementia of the Alzheimer type. J Am Geriatr Soc 1992; 40: 503–6 PubMedCAS Google Scholar
Laake K, Oeksengaard AR. D-cycloserine for Alzheimer’s disease. Cochrane Database Syst Rev 2002; 2: CD003153 PubMed Google Scholar
Tariot PN, Farlow MR, Grossberg GT, et al. Memantine treatment in patients with moderate to severe Alzheimer’s disease already receiving donepezil: a randomized controlled trial. JAMA 2004; 291(3): 317–24 ArticlePubMedCAS Google Scholar
van Dyck CH, Schmitt FA, Olin JT. Memantine MEMMD-02 Study Group. A responder analysis of memantine treatment in patients with Alzheimer disease maintained on donepezil. Am J Geriatr Psychiatry 2006; 14(5): 428–37 ArticlePubMed Google Scholar
Rountree SD, Chan W, Pavlik VN, et al. Persistent treatment with cholinesterase inhibitors and/or memantine slows clinical progression of Alzheimer disease. Alzheimers Res Ther 2009; 1: 7 ArticlePubMed Google Scholar
Atri A, Shaughnessy LW, Locascio JJ, et al. Long-term course and effectiveness of combination therapy in Alzheimer disease. Alzheimer Dis Assoc Disord 2008 Jul–Sep; 22(3): 209–21 ArticlePubMedCAS Google Scholar
Porsteinsson AP, Grossberg GT, Mintzer J, et al. Memantine treatment in patients with mild to moderate Alzheimer’s disease already receiving a cholinesterase inhibitor: a randomized, double-blind, placebo-controlled trial. Curr Alzheimer Res 2008 Feb; 5(1): 83–9 ArticlePubMedCAS Google Scholar
Peskind ER, Potkin SG, Pomara N, et al. Memantine treatment in mild to moderate Alzheimer disease: a 24-week randomized controlled trial. Am J Geriatr Psychiatry 2006; 14: 704–15 ArticlePubMed Google Scholar
Bakchine S, Loft H. Memantine treatment in patients with mild to moderate Alzheimer’s disease: results of a randomized, doubleblind, placebo-controlled 6-month study. J Alzheimers Dis 2007; 11: 471–9 PubMedCAS Google Scholar
Hartmann S, Möbius HJ. Tolerability of memantine in combination with cholinesterase inhibitors in dementia therapy. Int Clin Psychopharmacol 2003; 18: 81–5 ArticlePubMed Google Scholar
Yao C, Raoufinia A, Gold M, et al. Steady-state pharmacokinetics of galantamine are not affected by addition of memantine in healthy subjects. J Clin Pharmacol 2005; 45: 519–28 ArticlePubMedCAS Google Scholar
Shua-Haim JR, Smith J, Pass M, et al. Safety, tolerability, and caregiver’s impressions of combination therapy with galantamine and memantine for the treatment of Alzheimer’s disease [abstract P1-392]. Poster presented at the American Psychiatric Association 2004 Annual Meeting; 2004 Jul 17–22; Philadelphia (PA)
American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed. Washington, DC: American Psychiatric Association, 1994 Google Scholar
Ramaswamy K. Safety of galantamine-memantine combination treatment for mild to moderate Alzheimer’s disease. Poster presented at the 57th Institute on Psychiatric Services; 2005 Oct 5–9; San Diego (CA)
Olin JT, Bhatnagar V, Reyes P, et al. Safety and tolerability of rivastigmine capsule with memantine in patients with probable Alzheimer’s disease: a 26-week, open-label, prospective trial (Study ENA713B US32). Int J Geriatr Psychiatry 2010 Apr; 25(4): 419–26 ArticlePubMed Google Scholar
Farlow MR, Alva G, Meng X, et al. A 25-week, open-label trial investigating rivastigmine transdermal patches with concomitant memantine in mild-to-moderate Alzheimer’s disease: a post hoc analysis. Curr Med Res Opin 2010 Feb; 26(2): 263–9 ArticlePubMedCAS Google Scholar
Lopez OL, Becker JT, Wahed AS, et al. Long-term effects of the concomitant use of memantine with cholinesterase inhibition in Alzheimer disease. J Neurol Neurosurg Psychiatry 2009 Jun; 80(6): 600–7 ArticlePubMedCAS Google Scholar
Danysz W, Parsons CG. The NMDA receptor antagonist memantine as a symptomatological and neuroprotective treatment for Alzheimer’s disease: preclinical evidence. Int J Geriatr Psychiatry 2003; 18Suppl. 1: S23–32 ArticlePubMed Google Scholar
Reisberg B, Doody R, Stöffler A, et al. A 24-week open-label extension study of memantine in moderate to severe Alzheimer disease. Arch Neurol 2006 Jan; 63(1): 49–54 ArticlePubMed Google Scholar
Mohs RC, Kawas C, Carrillo MC. Optimal design of clinical trials for drugs designed to slow the course of Alzheimer’s disease. Alzheimer Dement 2006; 2: 131–9 ArticleCAS Google Scholar
Martinez-Coria H, Green KN, Billings LM, et al. Memantine improves cognition and reduces Alzheimer’s-like neuropathology in transgenic mice. Am J Pathol 2010 Feb; 176(2): 870–80 ArticlePubMedCAS Google Scholar